Bio-Techne Corporation (NasdaqGS: TECH)
Health Care · Life Sciences Tools & Services · US
$72.45
-0.11% today · +22.5% 1Y
Bio-Techne Corporation (NasdaqGS: TECH) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $11.37B and employs 3,000 people.
Over the last twelve months the share price has gained 22.5%, trading between 43.20 and 72.69.
Tweenvest scores Bio-Techne Corporation across four factors: quality 84/100, value 45/100, growth 30/100, dividend 27/100. Its strongest factor is quality.
TECH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.37B
- Revenue (TTM)
- $1.22B
- P/E
- 62.53
- EPS
- 1.16
- Dividend yield
- 0.44%
- Beta (5Y)
- 1.30
- 52-week high
- $72.69
- 52-week low
- $43.20
- Avg volume (3M)
- —
- Shares outstanding
- 156.82M
- Employees
- 3,000
- Next earnings
- —
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- ISIN
- US09073M1045
- Founded
- 1976
- Listed since
- Feb 9, 1989
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| WuXi XDC Cayman Inc.SEHK: 2268 | $13.01B | HK$80.60 | -0.49% |
| Genscript Biotech CorporationSEHK: 1548 | $12.71B | HK$43.72 | +1.82% |
| ICON Public Limited CompanyNasdaqGS: ICLR | $12.69B | $164.50 | +0.26% |
| Tempus AI, Inc.NasdaqGS: TEM | $12.50B | $69.28 | -1.52% |
| Pharmaron Beijing Co., Ltd.SZSE: 300759 | $11.36B | CN¥44.97 | +3.38% |
| Avantor, Inc.NYSE: AVTR | $10.38B | $15.39 | +0.26% |
| 10x Genomics, Inc.NasdaqGS: TXG | $9.92B | $77.28 | +1.55% |
| Bio-Rad Laboratories, Inc.NYSE: BIO | $9.82B | $360.40 | -2.04% |
Figures last refreshed Oct 4, 2026.